Inke Mathauer & Maarten Oranje

Need for health financing guidance and regulation for machine learning

This online first version has been peer-reviewed, accepted and edited, but not formatted and finalized with corrections from authors and proofreaders

Machine learning in health financing: benefits, risks and regulatory needs

Inke Mathauer\textsuperscript{a} & Maarten Oranje\textsuperscript{a}

\textsuperscript{a} Department of Health Financing, World Health Organization, 20 Avenue Appia, 1211 Geneva, Switzerland.

Correspondence to Inke Mathauer (email: mathaueri@who.int).

(Submitted: 2 June 2023 – Revised version received: 12 October 2023 – Accepted: 29 October 2023 – Published online: 8 December 2023)

Abstract

While the use of machine learning for health financing functions (revenue raising, pooling and purchasing) is increasing, evidence lacks for its effects on the objectives of universal health coverage (UHC). This paper provides a synopsis of the use cases of machine learning and their potential benefits and risks. The assessment reveals that the various use cases of machine learning for health financing have the potential to affect all the intermediate UHC objectives – the equitable distribution of resources (both positively and negatively), efficiency (primarily positively) and transparency and accountability (both positively and negatively). There are also both positive and negative effects on all three final UHC goals, that is, utilization of health services in line with need, financial protection and quality care. When the use of machine learning facilitates or simplifies health financing tasks that are counterproductive to UHC objectives, there are various risks, for instance risk selection, cost reductions at the expense of quality care, reduced financial protection or over-surveillance. Whether the effects of using machine learning are positive or negative depends on how and for which purpose the technology is applied. Therefore, specific health financing guidance and regulations, particularly for (voluntary) health insurance, are needed. To inform the development of specific health financing guidance and regulation, we propose several key policy and research questions. To gain a better understanding of how machine learning affects health financing for UHC objectives, more systematic and rigorous research should accompany the application of machine learning.

Introduction

Over the past 10 years, the number of publications on artificial intelligence and machine learning related to health financing tasks has markedly increased,\textsuperscript{1} in line with the trend of using artificial intelligence in digital health in general.\textsuperscript{2} Still, evidence lacks regarding the impact of artificial intelligence and machine learning on health financing and universal health coverage (UHC), as is true for the broader field of digital technologies for health financing.\textsuperscript{3–5}

Many countries, regardless of income level, are undertaking reforms in their health financing system to progress towards and achieve the UHC three intermediate objectives
(equitable use of resources, efficiency and transparency and accountability) and three final coverage goals (utilization in line with need, financial protection and quality care). Transparency and accountability pertain to the responsibility of health providers and purchasing agencies to provide information on their performance to each other, citizens, patients and health ministries. In Box 1 we summarize the health financing functions and their related policy decisions and tasks. A detailed explanation of how these functions contribute to UHC objectives and goals can be found elsewhere.

The World Health Organization (WHO) refers to artificial intelligence as “the ability of algorithms encoded in technology to learn from data so that they can perform automated tasks without every step in the process having to be programmed explicitly by a human.” Machine learning is one of the most prominent types of artificial intelligence. Machine learning uses statistical and mathematical modelling techniques, whereby algorithmic models are trained to recognize patterns and to make estimations or predictions based on these patterns without human interference.

There are different types of machine learning. In supervised learning, the data used to train a model are labelled (the input and respective outcome variables are known) and the model derives a function from the training data that can predict outputs from new input data. Unsupervised learning does not use labelled data but involves the identification of hidden patterns in the data. In semi-supervised learning, a small amount of labelled (training) data is combined with a large amount of unlabelled data. Machine learning is particularly useful in the analysis of big data, which are data sets that are too complex for traditional data processing methods. Volume, variety and velocity are properties defining these data sets. Without the use of machine learning, health financing tasks supported by data analysis are undertaken by traditional statistical methods or actuarial analysis.

Machine learning, like other digital technologies, may affect health financing and UHC objectives in various ways. Fig. 1 illustrates how digital technologies, specifically machine learning, interface with health financing functions and tasks, potentially enhancing intermediate and final UHC objectives. In an ideal scenario, machine learning would support, facilitate, enhance or simplify a health financing task or scheme or help inform health financing policy design that in itself is conducive to UHC. However, the use of machine learning can also have negative consequences. Inadequate design and/or flawed implementation of machine learning can harm a UHC conducive health financing task, scheme or policy design. Equally concerning is the use of machine learning in ways that, while supporting, enhancing, or
simplifying health financing tasks or schemes, or informing policy design, may not be conducive to UHC a priori.\textsuperscript{17}

With the increasing use of machine learning in health financing, we aim to provide an overview of machine learning use cases in health financing, and the risks and benefits of using machine learning in this field. First, we provide a synopsis of the potential benefits and risks of using machine learning as a means to progress towards the intermediate objectives and final UHC objectives. We then discuss notable policy implications and outline a range of key policy questions; with the aim of supporting country policy-makers, practitioners, researchers and development partners in their effective development and use of machine learning tools as well as artificial intelligence for UHC purposes.

**Machine learning in health financing**

Building on existing literature,\textsuperscript{1} we have identified the main domains of health financing in which machine learning is currently being used in-country or for which theoretical modelling exercises and model comparisons have been undertaken by researchers. Of note, there are only a few documented and published country use cases of machine learning for health financing. We have extracted the benefits and risks of using artificial intelligence in health financing from several review papers\textsuperscript{1,18,19} and have deductively derived the main implications in relation to UHC objectives. Table 1 presents the domains of health financing in which machine learning is used and the types of machine learning applied as well as summarizes the risks and benefits. We discuss eight domains in health financing for which machine learning is used; cutting across all health financing functions, with an emphasis on purchasing. As illustrated in Table 1, both supervised and unsupervised models are being used. Both in-country uses and modelling exercises of machine learning for health financing show potential to affect intermediate UHC objectives. The efficiency objective is primarily positively affected by applying machine learning, while equitable distribution of resources and transparency are both positively and negatively affected. Furthermore, machine learning can have both positive and negative effects on all three final UHC goals.

As the use of machine learning in health financing is rapidly evolving, we are aware that this overview of use cases and benefits and risks is not exhaustive nor complete. The use cases covered here comprise all WHO regions. In the rapid literature review,\textsuperscript{1} covering 38 studies, for instance, 58% (22 studies) of these are based on data from high-income countries,
with more than half (12 studies) coming from the United States of America, while the rest used data from low-and middle-income countries.

There are assumingly further machine learning applications in health financing, for instance in voluntary health insurance. These applications appear to be neither systematically documented nor published yet, and would eventually complement this overview.

Additionally, machine learning can be applied to areas adjacent to health financing, such as procurement, supplier selection, and the optimization of hospital (financial) management practices. These include improving diagnosis-related grouping systems, implementing cost-containment measures, and optimizing resource allocation to increase the financial efficiency of hospitals.¹ We also observe that many of the identified machine learning use cases have been applications that support health insurance related tasks, which suggests to us that potential uses of machine learning in health financing have not yet been sufficiently explored for other health coverage schemes.

**Benefits**

The main advantages of machine learning lie in the higher accuracy and enhanced speed in generating results in comparison to traditional statistical methods or conventional prediction models, as data processing and analysis can be automated. Increased accuracy and speed may also result in (administrative) cost reductions for the different health financing actors, such as purchasers, providers and stewards, particularly in relation to claims management and fraud detection,¹⁹,²⁰ as practically applied in an increasing number of countries.²¹–²⁴ Also numerous theoretical modelling exercises show these benefits. For instance, a study using public health insurance data from Ghana, designed and evaluated algorithmic models that served to classify health insurance claims into legitimate and fraudulent claims; demonstrating improved accuracy in classification while also considerably decreasing processing time.²⁵ In another instance, data from a performance-based payment programme for health centres in Zambia was used to test various machine learning techniques to identify which health centres require verification of their reported performance. The model showed that targeted verification, as opposed to undifferentiated verification of all providers, might provide cost savings by reducing the number of fraudulent claims and unnecessary verification.²⁶

Machine learning can also be useful in the prediction of health-care expenditure, the targeting and identification of beneficiaries and the selection of providers. For example, several supervised machine learning techniques were tested to predict the development of Swiss
patients’ health-care costs and to identify factors contributing to its increase or decrease. These findings could enable policy-makers to improve resource allocation planning, optimizing health service delivery through targeted disease management programmes for high-cost patients.27

Machine learning models may also reveal patterns in the available data, such as specific patient attributes, that otherwise may remain hidden. For example, a study using data from a nationwide health survey in Portugal applied unsupervised learning to identify clusters within the uninsured population, finding three segments with distinct sociodemographic characteristics and health-related needs. This information could be used to inform benefits design and policies to improve access to health care.28 Finally, machine learning could bring an advantage in technical or administrative processes where there are potential conflicts of interest or rent seeking implications. Since human-to-human interactions are minimized, there is less likelihood of discriminatory practices, for instance in relation to identifying households eligible for subsidization of health coverage.

Risks
In addition to the possible benefits, there are also critical risks. A generic problem, beyond the health financing sector, is the use of insufficient or unrepresentative data to train algorithms as well as bias in their design; exacerbating inequities or even leading to exclusion of certain population groups from benefits.29

Other ethical issues, which can create negative outcomes if not properly addressed relate to: (i) enduring digital divides between different population groups (in terms of income, gender, remoteness); (ii) use of poor quality data when no other data is available; (iii) mixed effects of predictive analytics; and (iv) lack of clarity about the degree of machine learning-influenced decision-making.14 Specific risks for health financing relate to the use of machine learning that facilitates, simplifies or supports actions that are counterproductive to UHC objectives, such as risk selection, cost reductions at the expense of quality of care or financial protection or excessive monitoring that could create mistrust for instance by providers towards purchasing agencies. For instance, there is a risk that, instead of using machine learning-derived insights to tailor benefits and improve access for underprivileged and vulnerable groups, these insights might be misused to identify patterns in health expenditure and service utilization that exclude certain groups. Using such data could lead to the exclusion of high-cost
patients or certain conditions from health coverage or facilitate raising insurance premiums for high-cost individuals.\textsuperscript{1,18,19}

For example, a major private health insurance company in South Africa applied machine learning to their customers’ data accrued from supermarket purchases and activities in fitness firms and health-care use at facilities to assess healthy behaviour in their customers. This information was used to assess healthy behaviour, with financial rewards, through lower premiums, offered to selected customers.\textsuperscript{30} However, from a health-financing perspective, this approach risks fragmenting the coverage and may discriminating against those most in need of health coverage.

**Guidance and regulations**

Whether the effects of machine learning on health financing are positive or negative also strongly depends on how and for which purpose the technology is applied, for instance whether it is used for risk adjustment supporting defragmentation or risk selection leading to desolidarization. In addition to general considerations for applying machine learning and artificial intelligence in health care – which includes establishing a comprehensive ethical framework, ensuring data governance and data protection, and upholding value-based principles\textsuperscript{14,31,32} – it is imperative to implement tailored regulatory measures for health financing. Such regulation is particularly pertinent for voluntary commercial health insurance, considering its potential to fragment health systems and its inherent profit-driven motivations, which could lead to practices aimed at minimizing insurer costs at the expense of broader health system goals.

Regulatory frameworks must mandate clear, accountable procedures that not only secure informed consent from individuals but also clearly disclose the use of health-related data and how it is being used. Equilibrium must be achieved between protecting personal data and fulfilling the legitimate information requirements of purchasing agencies. Furthermore, multisectoral stakeholder consultation processes and governance arrangements are required, in which insurers, regulatory bodies and policy-makers work together for the public interest and system benefits.\textsuperscript{18} Risk mitigation measures could also include algorithm auditing and quality control,\textsuperscript{33} as well as algorithm validation, for example through the analysis of secondary data.

Importantly, algorithms used in health financing need to be presented in such a way that they can be explained and made visible by humans.\textsuperscript{29,34} Human judgment should be supported and complemented by machine learning, not replaced by it, ensuring that human oversight remains a core standard in the use of artificial intelligence and machine learning.\textsuperscript{32} The need
for human oversight is also acknowledged by the European Union’s General Data Protection Regulation, which does not permit insurance claim denials based solely on algorithms. In a similar vein, meaningful human oversight is a core principle of the Artificial Intelligence and Data Act in Canada; tabled in 2022 and expected to enter into force in 2025 or soon after.

We argue that a more fundamental societal discussion is needed regarding the desirability of artificial intelligence and machine learning in health financing to support the development of regulatory provisions. The recently published WHO guidance note on regulatory requirements related to artificial intelligence in health will be instrumental in that respect and can be further operationalized for health financing.

In Box 2 we propose several key policy and research questions that can be used to inform the development of and discussion about health financing specific guidance and regulation of ethical and UHC-oriented machine learning use. We assert that multidisciplinary collaboration is required to address these questions by involving health-financing policy experts, legal practitioners, artificial intelligence and machine learning specialists, as well as other disciplines. This collaboration should also expand to the design and execution of studies on the effects of artificial intelligence and machine learning as well as the validation of machine learning techniques since diverse teams will be better positioned to avoid neglecting or underrepresenting the key variables of certain population groups. To establish and maintain functional collaborative governance platforms, health financing stakeholders must be equipped with the institutional, technical and regulatory capacity and the adequate human resources to manage and oversee the deployment of artificial intelligence in health financing. There is also need to create and strengthen algorithmic awareness or algorithmic literacy among health financing system stewards, as well as among citizens, patients, providers and purchasers in relation to health financing. The list in Box 2 is not exhaustive and further policy relevant regulatory and research issues will surely be identified as the field of artificial intelligence and machine learning continues to evolve.

The recent emergence of generative artificial intelligence systems based on natural language processing demonstrates this dynamic nature of artificial intelligence and machine learning. In the future, generative artificial intelligence may enter the policy formulation domain and will thus require a fitting government response. Governments will need to regulate the extent to which generative artificial intelligence can be used to support health financing policy development and create machine learning models used for health financing. These
regulatory needs constitute non-trivial questions that will have to be answered for all public policy fields including health financing; and more research will be needed.

Whenever the use of machine learning is considered, it is necessary to carefully weigh the benefits and risks to avoid scenarios in which unforeseen or foreseen negative effects outweigh the positive ones. In line with “cautious optimism with safeguards,” more and rigorous research and systematic evidence should accompany the application of machine learning so as to better understand its effects for health financing oriented towards UHC. We hope that more country-based use cases will be documented and published to inform our guidance and policy development, and the WHO document *Assessing the effects of digital technologies on health financing and universal health coverage objectives: a guide with key questions* provides guidance in that respect.17

In conclusion, only when ethical questions and regulatory issues are properly addressed, the use of artificial intelligence and machine learning for health financing will contribute to the progressive realization of UHC.

**Acknowledgements**

We thank Jaidev Anand, Dennis Batangan, Fahdi Dkhimi, Triin Habicht, Natschja Nash-Mendez, Sameer Pujari, Lluis Vinals Torres and MyMai Yuan.

**Competing interests:**

None declared

**References**


17. Digital technologies for health financing: assessing their effects on desirable health financing attributes and universal health coverage objectives: a guide with key

18. Ho CWL, Ali J, Caals K. Ensuring trustworthy use of artificial intelligence and big
data analytics in health insurance. Bull World Health Organ. 2020 Apr

the power of artificial intelligence with the richness of healthcare claims data:
https://doi.org/10.1007/s40273-019-00777-6 PMID:30848452

20. Hassan AKI, Abraham A. Computational intelligence models for insurance fraud

based on data mining: a case study in Chile. In: Proceedings of the 2006
International Conference on Data Mining; 2006 Jun 26–29; Las Vegas, USA.
Berlin: ResearchGate GmbH; 2006. Available from:
https://www.researchgate.net/publication/220704891_A_Medical_Claim_Fraud
Abuse_Detection_System_based_on_Data_Mining_A_Case_Study_in_Chile
[cited 2023 Oct 16].

22. The role of digital claims management for Estonia’s health insurance: a leverage
for making healthcare purchasing more strategic. Geneva: World Health
[cited 2023 Mar 3].

23. Digital technologies for government supported health insurance systems in Asia
https://www.adb.org/sites/default/files/publication/761111/digital-technologies-
health-insurance-systems-asia-pacific.pdf [cited 2023 Oct 16].

24. Pague B, Alcantara AC. Claims management using artificial intelligence:
experiences from PhilHealth in the Philippines. In: 2021 World Congress on
Health Economics, 2021 Jul 12–15, virtual congress. Virtual congress: Toronto:
International Health Economics Association; 2021. Available from:

support system (DSS) for fraud detection in health insurance claims using
https://doi.org/10.1155/2019/1432597

26. Grover D, Bauhoff S, Friedman J. Using supervised learning to select audit targets
PMID:30695057

of health care expenditure increase: how does pharmacotherapy contribute?
019-4616-x PMID:31829224


Box 1. Definitions of revenue raising, pooling and purchasing

- Revenue raising is the process of raising money to pay health system costs, for example through taxation and health insurance contributions. Revenue raising includes policy decisions and tasks related to the sources and levels of contributions, and the mechanisms to collect these funds.

- Pooling is the accumulation and aggregation of prepaid funds, so that the financial risk of having to pay for health care is shared by all members of the pool. Pooling includes decisions and tasks related to targeting and identification of population groups for subsidized health coverage as well as risk adjustment or cross-subsidization across risk pools.

- Purchasing is the process of allocating these prepaid and pooled funds from purchasers to health-care providers. Purchasing includes decisions and tasks related to selection and contracting of providers, the provider payment methods and rates. Closely related to purchasing is benefits design, which concerns decisions on service and cost coverage, cost-sharing rates and exemptions.\textsuperscript{11}
Box 2. Proposed policy and research questions about the use of machine learning or artificial intelligence in health financing

**Responsible use of data and big data analytics**

What kind of health financing related and other governmental or nongovernmental databases should actors be allowed to use and combine? Which data should actors not be allowed to use?

**Managing the capitalization of data**

Which (health financing) actors should have access to health financing relevant data and under which conditions or requirements? Which health financing stakeholders should be involved in setting the costs to provide access to data? Who should pay for health financing related data?

**Generating quality data for training and applications of machine learning models**

How to ensure that health financing data is comprehensive and representative to counteract the risk of algorithmic bias and discrimination of individuals or vulnerable population groups (such as low-income groups, women, rural populations) in relation to access to care, quality of care, resource allocation and financial protection?

**Balancing and addressing conflicts of interests in relation to predictive analytics:**

What are the legitimate needs and rights of an individual (i.e. the right to not want to know about future health-care needs and costs) weighed against a purchaser’s interests in predictive analytics to support health financing decisions and policy design?

**Exploring limits to the use of machine learning**

Should certain uses of machine learning in health financing and health insurance be restricted, such as for risk selection (e.g. under voluntary health insurance), or for the identification of high-cost patients?

**Determining the desired degree of digitality**

How much artificial intelligence and machine learning supported decision-making is desirable in the health financing domains, and how much human control should health financing stewards maintain?

**Regulating accountability lines and liability**

Who should be held accountable or liable for errors or harm due to the use of artificial intelligence and machine learning in health financing?

**Setting effective regulatory provisions for the decision-making processes on artificial intelligence and machine learning in health financing**

How should the decision-making, development and revision process of regulatory provisions relating to artificial intelligence and machine learning be organized in view of the speed of technological changes?

**Ensuring the monitoring of machine learning effects**

What kind of information and monitoring systems and processes are needed to ensure that machine learning algorithms have no inequitable and harmful effects in relation to vulnerable population groups (such as low-income groups, women, rural populations)?
### Table 1. Uses of machine learning in health financing and their potential risks and benefits

<table>
<thead>
<tr>
<th>Domain of use (function)</th>
<th>Type of application</th>
<th>Potential benefits</th>
<th>Risks</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prediction of health expenditure or healthcare costs, also in relation to specific diseases or in relation to use by specific individuals or groups (revenue raising, purchasing)</td>
<td>Supervised learning (classification, variable selection, regression, prediction)</td>
<td>Through the revelation of hidden patterns in data (such as specific patient attributes or use patterns), more accurate cost predictions are possible (compared to traditional statistical methods), e.g. for specific diseases, for high-cost patients and for improved service tailoring (e.g. optimized disease management and prevention activities for specific population groups). These insights can contribute to better forecasting, more efficient spending, more equitable resource distribution and improved utilization in line with need.</td>
<td>Predictive analytics could be used for the exclusion of high-cost diseases and introduction of cost-reduction measures at the expense of financial protection and quality of care. Predictive analytics endangers a person's privacy, i.e. a person may not give consent for predictions to be made based on their personal data.</td>
</tr>
<tr>
<td>Assessment of health risks in a pool (i.e. calculating patients' health risk scores, a metric to predict aspects of a patient’s future care (e.g. comparing costs, risk of hospitalization of a patient with the average) (pooling)</td>
<td>Supervised learning (regression, variable selection)</td>
<td>More precise risk scoring through machine learning supported data analysis can improve risk adjustment or risk equalization mechanisms and formulas, which serve to ensure equalized per capita allocations or expenditure that reflects differences in health risks and needs across different pools. More precise scoring can contribute to more efficiency and equitable allocation of resources.</td>
<td>More precise risk scoring may facilitate risk selection and the exclusion of high (cost) users or otherwise vulnerable groups from health insurance, or the increase of their premiums (based on medical underwriting). These practices could lead to further fragmentation of risk pools and hence reduced equity in resource distribution, as well as increased inequity in access to care and reduced financial protection.</td>
</tr>
<tr>
<td>Claims review and fraud detection (purchasing)</td>
<td>Mostly supervised learning (classification), some examples of unsupervised learning (clustering/outlier detection)</td>
<td>By identifying patterns, machine learning supported claims review can improve and accelerate: preauthorization of patient care; claims adjudication (the checking of validity and eligibility); proactive identification of coding and billing errors before claims processing and payment; and detection and investigation of outliers and duplicate claims. These improvements can result in reduced claims processing time, reduced human resources needed for claims review, reduced administrative costs, less erroneous payments and higher overall efficiency.</td>
<td>Machine learning supported claims management may enable more advanced, thus simplified opportunities for surveillance of health service providers by the purchaser, potentially leading to a culture of fault-finding and mistrust among providers towards the purchaser. Machine learning supported claims management could reduce the role of human judgment in claims review, which could lead to a lack of transparency and explicability of outcomes of purchasing agencies, and as a</td>
</tr>
</tbody>
</table>
Prudence in claims preparation by providers can be enhanced (less gaming) and lead to higher transparency and accountability of health providers and purchasing agencies in their claims management activities. Possible synergy between automated (machine learning supported) claims review and review by humans (whereby the former can support the latter) might lead to less subjectivity and errors (more transparency of purchasing agencies in their claims review decisions). The use of machine learning results can provide more granular and more accurate insights to inform policy decisions on: provider payment methods and rates; and quality improvement, based on comparison of treatment practices across providers. Such policy decisions can result in improved efficiency, more equitable distribution of resources and more equitable access to care, financial protection and improved quality of care.

Machine learning supported data analysis may suffer from algorithmic bias and/or use of insufficient or unrepresentative data. Bias could lead to unintended, distorted outcomes, including unequal treatment of providers and potential market distortions. Lack of explicability of the working and outcomes of machine learning to health-care providers could erode trust.

### Design or revision of provider payments through claims analysis (purchasing)

| No information on the applied types of machine learning |

### Provider performance and contract monitoring by purchasers (purchasing)

| No information on the applied types of machine learning |

### Design of benefits and access conditions based on claims analysis (purchasing)

| Unsupervised learning (clustering); also supervised learning (regression/prediction) |

### Identification of beneficiaries for targeting policies

| Supervised learning (classification, variable selection, |

Machine learning-based claims analysis can provide more granular insights on patient needs and expenditure trends to inform policy decisions on premiums and co-insurance rates (as cost determinants become clearer) and health needs-oriented benefits design. Using these insights for policy decisions can result in increased efficiency, more equitable distribution of resources and equitable access to care, quality of care and responsiveness to patient preferences and needs, and financial protection.

Precision and efficiency can be increased in targeting processes for poor and/or vulnerable beneficiaries of government funded health coverage or cash transfer.

### Machine learning supported data analysis may facilitate algorithmic bias and/or use of insufficient or unrepresentative data for policy decisions, potentially leading to unintended and distorted outcomes, including discrimination against individuals or population groups and increasing inequities in resource distribution. Lack of explicability of the working and outcomes of machine learning to beneficiaries could erode trust of people in social protection schemes and programmes.
Combination of data from multiple databases can increase opportunities for surveillance and lack of privacy

Beneficiary enrolment (pooling)

Supervised learning (classification)

Identity confirmation, identification of beneficiaries and timely enrolment can be improved, which can reduce coverage gaps (exclusion errors) and increase financial protection. Validation of data entry in beneficiary databases, e.g. through identity confirmation and authentication support processes, improves data quality. As a result, fraud, abuse, inclusion errors and unnecessary data collection can be reduced

Source: Compilation of various review papers. 1,18,19
Fig. 1. Linkages between machine learning models, health financing functions and UHC objectives and goals

UHC: universal health coverage.

Source: Adapted from World Health Organization.